# Next Generation pErsonalized tX(Therapy) With Plasma DNA Trial-2 in Refractory Solid Tumors (The NEXT-2 Trial)

> **NCT02140463** · — · COMPLETED · sponsor: **Samsung Medical Center** · enrollment: 229 (actual)

## Conditions studied

- Metastatic Gastrointestinal Cancer
- Genitourinary Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02140463
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2019-07
- **Final completion:** 2019-10-29
- **Target enrollment:** 229 (ACTUAL)
- **Last updated:** 2022-06-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02140463

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02140463, "Next Generation pErsonalized tX(Therapy) With Plasma DNA Trial-2 in Refractory Solid Tumors (The NEXT-2 Trial)". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT02140463. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*